Ipsen Signs Exclusive Worldwide License Agreement with Blueprint to Develop & Commercialize BLU-782 for Fibrodysplasia Ossificans Progressiva

Ipsen Signs Exclusive Worldwide License Agreement with Blueprint to Develop & Commercialize BLU-782 for Fibrodysplasia Ossificans Progressiva

Shots:

  • Blueprint to receive $535M including $25M up front and up to $510M as development, regulatory & commercial milestone for BLU-782 in up to two indications, including FOP with royalties on global sales of BLU-782
  • The collaboration robust Ipsen’s rare diseases portfolio and accelerates Blueprint’s aim to globally develop BLU-782 by utilizing Ipsen’s clinical expertise in rare diseases and global infrastructure
  • Blueprint’s BLU-782 is a selective ALK2 inhibitor, being evaluated in P-I study and has received FDA’s rare pediatric disease designation, orphan drug designation and fast track designation for the treatment of FOP

Click here to­ read full press release/ article | Ref: Ipsen | Image: Genetic Engineering and Biotechnology News